

Table S1. Data on N (no. of patients), number of fibroids, starting uterine and fibroid volumes for the included studies.

Author	Year	Modality	N	No. of fibroids	Ut Vol	SD	Fib vol	SD/IQR
Ghezzi (46)	2007	Laparoscopic RFA	25	R 1 - 3			76.8	R14.8-332.8
Cho (47)	2008	Transvaginal RFA	139				MAF 65.12	
Garza Leal (48)	2011	Laparoscopic RFA	31	64.5% single, R 1-8	194.4	105.9		
Kim (49)	2011	Transvaginal RFA	69	26.1% single			304.6	229.1
Robles (50)	2013	Laparoscopic RFA	35		232.2	145		
Chudnoff (16)	2013	Laparoscopic RFA	127				MAF 80.4	84.4
Galen (14)	2014	RFA phase II (1)	69	M 3	204.4			
		RFA phase III (2)	139	M 4	303.1			
Jiang (51)	2014	Transvaginal RFA	46	60.9% single			67.4	51.1
Yin (15)	2015	RFA pre-menopausal (1)	476	M 1.7			MAF 47.6	29.5
		RFA 'post menopausal' (2)	740	M 2.6			65.4	47.7
Bröllman (52)	2016	Transcervical RFA	49	89 total; M 2.4 +/- 1.7, R 1-7			18.8	21.4
Wu (53)	2016	Transvaginal RFA	51	82% single			33	R 0.8-77.9
Roth (54)	2000	UAE	71		691.9	419.2	244.5	274.6
Brunereau (55)	2000	UAE	58		105.6	36.6	57	29.1
Andersen (56)	2001	UAE	30				MAF 162	R 19-726
Tranquart (57)	2002	UAE	58		305	R 65-1403	112	R 10-723
Banovac (58)	2002	UAE	23	61 fibroids in total	568	R101-1608	118	R 12-728
Messina (59)	2002	UAE	26		385			
Watson (60)	2002	UAE	114	165 in total				
Pinto (61)	2003	UAE	40	M 1.6 +/- 0.5	84.42		72	86
Zupi (62)	2003	UAE	26		276.8	241.2		
Pron (28)	2003	UAE	538	30% single	704	586	308	380
Spies (63)	2004	UAE	102	26% single	689.4	466.1	146.8	158.5

Khaund (64)	2004	UAE	50					
Huang (65)	2004	UAE	30	88% single	281.6	137.4	MAF 88.3	100.6
Healey (66)	2004	UAE	68	16.3% single	538	50	154	19.9
Smith (67)	2004	UAE	80		678.4	R 97.8-2366		
Shan (68)	2004	UAE	99	88% single				
Spies (69)	2005	UAE	175	14.8% single	717	CI 648.8 - 785.2	240	CI 200.8 - 279.3
Goodwin (70)	2005	UAE	149	9% single	658.4		182.12	208.98
Mohan (71)	2005	UAE	28		308	R 158-1003		
Kim (21)	2006	UAE - UO anastamoses (1)	116		684.2			
		UAE – no UO anastamoses (2)	172		761.3			
Lohle (30)	2006	UAE	126		532	375	201	249
Siskin (72)	2006	UAE	77	15.6% single, R 1-11	706.4 (n 72)	R 134-3101	79	
Scheurig (27)	2006	UAE	82	23% single	324.8	R 231.8-459.9	85.6	R 27.7-176.9
Volkers (32)	2006	UAE	87	M 2, R 1-20	471.9	450	121.5	150
Jain (73)	2007	UAE	32	68.75% single				
Chrisman (74)	2007	UAE	24		1434	251 cm	423	104
Pakiz (75)	2008	UAE	60				245.5	
Toor (19)	2008	UAE success (1)	58	M 2.97	845	537.7	282.5	264.8
		UAE failed (2)	20	M 2.5	733	535.4	337.6	381
Mara (76)	2008	UAE	58	67.2% single			166	
Firouznia (77)	2008	UAE	101	40.5% single	600.5	657.7	248.1	365.1
Hirst (78)	2008	UAE	178	14.2% single				
Lohle (79)	2008	UAE	100	33% single	510	R 54-1750	170	R 2-1123
Hald (31)	2009	UAE	26	69% 1-2 fibroids	598	R 171-1276	257	R 35-530
Pisco (80)	2009	UAE	234	23.1% single	448.7		MAF 110.5	
Naguib (81)	2010	UAE	28	M 2.77				79.3
Sone (82)	2010	UAE	33	27% single			321	R 171-426
Smeets (83)	2010	UAE	86		541	R 63-1929	185	R 4-1373

Stampfl (84)	2011	UAE	121	15% single			137.2	245.1
Bilhim (20)	2011	UAE - small particles (1)	80	35% single	515		210	
		UAE - large particles (2)	80	31.3% single	482		193	
Tomislav (85)	2011	UAE	152		860		385	
Kisilevzky (86)	2011	UAE	100	24% single	454.8	333.4	155.5	221.7
Mara (87)	2012	UAE	90	M 2.4 +/- 2.4, 53% single R1-13			188.7	39.6
Horhoianu (88)	2012	UAE	31	M 1.67 +/- 0.9, R 1-4, 58% single	293.6	192.13	64.27	77.88
Sasa (89)	2012	UAE	25					
Song (22)	2013	UAE - sponge (1)	30	23.3% single	960.27	558	265.26	339.01
		UAE - alcohol (2)	30	33.3% single	934.47	320.78	184.11	141.3
Das (90)	2013	UAE	50		869.8		416.3	
Choi (91)	2013	UAE - Large tumour (1)	63	49.2% single	855.8	277.1	443	319.6
		UAE - other tumours (2)	260	39.6% single	313.5	142.8	117.1	89.4
Ikink (23)	2014	UAE	68	34% Single, R 1-10	486	IQR 347-689	166	IQR 65-236
Laios (92)	2014	UAE	118		118.6	32.7	538.48	580
Dueholm (33)	2014	UAE	114	38% 1-2 fibroids			104	5-95centile 7-831
Czuczwar (93)	2014	UAE	65				101	R 23.6 - 610
McLucas (94)	2015	UAE	20		988.9	694.7		
Izumi (95)	2015	UAE - porous gelatin particles (1)	51	8% single			254.4	R 9-909
		UAE - Hand cut gelatin sponge (2)	64	17% single			332.9	R 14 - 1758
Hindley (96)	2004	MRgFUS	109	55% single				
Rabinovici (97)	2007	MRgFUS	35				250	236
Lenard (98)	2008	MRgFUS	66	71 in total			255.5	201.7
Morita (99)	2008	MRgFUS	48	55 in total				
Funaki (26)	2009	MRgFUS	91	64 % single, 141 in total				
Ren (100)	2009	USgHIFU	145	64.8% single			62.8	77.3
Le Blang (101)	2010	MRgFUS	80				175	201
Kim (102)	2011	MRgFUS	40	51 in total	978.7	CI 925.1 - 1032.3	336.9	CI 295.2 - 378.6

Dobrotwir (103)	2011	MRgFUS	100				185	174
Desai (104)	2012	MRgFUS	50	M 1.2 +/- 0.5, 68% single				
Leung (105)	2013	USgHIFU	20	22 in total			216.6	CI 55.7 - 294.4
Park (24)	2014	MRgFUS	64	M 1.5 +/- 1.1, R 1-8				
Ikink (23)	2014	MRgFUS	51	24% Single, R 1-10	792	IQR 454-478	273	IQR 142-478
Zhao (25)	2014	USgHIFU	42	51 in total				
Han (106)	2014	MRgFUS	37	50 in total			105.1	R 3.2 - 601.4
Himabindu (107)	2014	MRgFUS	32	51 fibroids in total			MAF 146.81	64.98
Tung (108)	2015	MRgFUS	40				258.1	223.8
Thiburce (109)	2015	MRgFUS	36	0% single, R2-5			255	CI 190-319

The number of fibroids are stated as a mean with standard deviation or the percentage of patients who had a single fibroid or the range of number of fibroids.

Table S2. Summary of reported fibroid volume reductions.

Author	Year	Modality	1 month	3 months	6 months	9 months	12 months	24 months	36 months
Ghezzi (46)	2007	Laparoscopic RFA			68.80%		77.9% (n 24)	78.6% (n 18)	83.9% (n 9)
					R 32.7-97.4%		R 13.6 - 98.2%	R 5-98.2	R 61.1-96.7%
Cho (47)	2008	TV RFA						73% (18 months)	
Kim (86)	2011	TV RFA	19.40%	52%	68.60%		74%		
Chudnoff (16)	2013	Laparoscopic RFA		39.8% (n 114)			45.10%		
				CI 35.6-44.1%			CI 38.6 - 51.6%		
Jiang (51)	2014	TV RFA		53.80%	72.10%		83%		
Yin (15)	2015	RFA (1)	39.80%	70.40%	78.40%		84.80%	88.30%	
		RFA (2)	16.90%	59.50%	71.30%		90.30%	90.30%	
Brölmann (17)	2016	Transcervical RFA		54.70%			66.6% (n 28)		
				SD 31.9%			SD 32.1%		
Wu (53)	2016	TV RFA	28%	57%	63%	78%			
Roth (54)	2000	UAE		40%					
				SD 28%					
Brunereau (55)	2000	UAE		23% R 0-100%	43 (n 46) R 0-100%		51% (n 27) R 25-100%		
Andersen (56)	2001	UAE			68%				
Tranquart (57)	2002	UAE		29%	46% (n 46)		55% (n 36)	86% (n 19)	
Banovac (58)	2002	UAE		52%					
				CI 40-69%					
Watson (60)	2002	UAE			58%				
Pron (28)	2003	UAE		42%					
Spies (63)	2004	UAE		45.80%	54%				
Huang (65)	2004	UAE			54.9% (8 months)				
					SD 66.5%				
Healey (66)	2004	UAE		38.20%	37%				

[illegible]

Hirst (78)	2008	UAE			47.3% (n 162)				
					SD 36.2%				
Lohle (79)	2008	UAE		44%	53%	61%			
Hald (31)	2009	UAE			62.80%				
					SD 27%				
Pisco (80)	2009	UAE			39.30%				
Naguib (81)	2010	UAE		52.62%			73.27%		
				SD 21.85%			SD 17.25%		
Sone (82)	2010	UAE		43.7% (n 32)	53.6% (n 32)		61.4% (n 30)		
Smeets (83)	2010	UAE		45%					
Stampfl (84)	2011	UAE		52%	78%		91%		
Bilhim (20)	2011	UAE (1)			56.70%				
		UAE (2)			49.20%				
Tomislav (85)	2011	UAE		46%	61%		66%		
Kisilevzky (86)	2011	UAE		57.10%					
				SD 25%					
Mara (87)	2012	UAE			53%				
Sasa (89)	2012	UAE			67.90%				
Horhoianu (88)	2012	UAE	27%						
Song (22)	2013	UAE (1)		60.21%					
				SD 18.07%					
		UAE (2)		47.89%					
				SD 20.85%					
Das (90)	2013	UAE			35%				
Choi (91)	2013	UAE (1)		46.5% SD 21.6%					
		UAE (2)		52% SD 25.6%					
Laios (92)	2014	UAE		20%			7.50%		
Ikink (23)	2014	UAE		43.30%					
				IQR 29.9-65.0%					

Dueholm (33)	2014	UAE			49.70%				
					SD 24.7%				
Czuczwar (93)	2014	UAE		50.1% R 2.7-93.5%					
Izumi (95)	2015	UAE (1)	45% SD 25%	56% SD 27%		62% SD 28%	66% SD 29%		
		UAE (2)	45% SD 24%	57% SD 21%		63% SD 27%	68% SD 32%		
Hindley (96)	2004	MRgFUS			13.5% SD 32%				
Rabinovici (97)	2007	MRgFUS		12% (n 24)			15% (n 29)		
				SD 16%			SD 27%		
Morita (99)	2008	MRgFUS			33%				
					SD 19%				
Lenard (98)	2008	MRgFUS			12.6% SD 16.9%		9.3% SD 24.8%		
Funaki (26)	2009	MRgFUS			36.50%			39.50%	
Ren (100)	2009	USgHIFU	22.20%	27.20%	47.9		50.30%		
Le Blang (101)	2010	MRgFUS			31% SD 28%				
Kim (102)	2011	MRgFUS			18.70%		25.80%	27.60%	
Dobrotwir (103)	2012	MRgFUS		29% (4 months)			38% (n 32)		
				SD 32%			SD 45%		
Desai (104)	2012	MRgFUS			30% SD 11%				
Leung (105)	2013	USgHIFU		17.2% CI 4.2-26.6%					
Himabindu (107)	2014	MRgFUS			40%				
Han (106)	2014	MRgFUS			41.6% (n 30) SD 23.2%				
Park (24)	2014	MRgFUS		21% SD 26%					
Ikink (23)	2014	MRgFUS		17.20%					
Zhao (25)	2015	USgHIFU			50.3%				

					R 39.2-65.5%				
Thiburce (109)	2015	MRgFUS			27% CI 19-35				
Tung (108)	2016	MRgFUS			31.70%				

Table S3. Summary of reported uterine volume reductions.

Author	Year	Modality	1 month	3 months	6 months	9 months	12 months	24 months
Garza Leal (48)	2011	Laparoscopic RFA		18%	24.3% (n 29)		41.8% (n 19)	
Robles (50)	2013	Laparoscopic RFA		16.70%	21.60%		23.60%	
Chudnoff (16)	2013	Laparoscopic RFA		15.70%			24.30%	
				CI 11-20.4%			CI 18.7-30	
Galen (14)	2014	RFA (1)		20.30%	25.20%		28.70%	
		RFA (2)		14.6% (n129)	20.6% (n128)		25.7% (n 127)	
Roth (54)	2000	UAE		30%				
				SD 21%				
Brunereau (55)	2000	UAE		13% R 0-50%	23% (n 46) R 0-55%		26% (n 27) R 0-60	
Tranquart (57)	2002	UAE		17%	26% (n 46)		37 (n 36)	45% (n 19)
Banovac (58)	2002	UAE		32%				
				CI 23-43%				
Messina (59)	2002	UAE		29%				41%
Pron (28)	2003	UAE		35%				
Zupi (62)	2003	UAE			55%		75%	
					SD 16.9%		SD 13.3%	
Pinto (61)	2003	UAE			46%			
Spies (63)	2004	UAE		26%	33.10%			
Khaund (64)	2004	UAE			40% (n 46)			
					CI 33-49.7%			
Huang (65)	2004	UAE			40.2% (8 months)			
					SD 24.8%			
Healey (66)	2004	UAE		19.30%	32.90%			
Smith (67)	2004	UAE		26.3% (4.3 months)			40.7% (11.2 months)	
Shan (68)	2004	UAE		42%	48%			
				R 0-76%	R 0-78%			
Goodwin (70)	2005	UAE		30%	38.60%			
Mohan (71)	2005	UAE			47%			62.60%

Spies (69)	2005	UAE		28.5% CI 24.7-32.3			39.4% (n 124)	
Kim (21)	2006	UAE (1)				49.50%		
						SD 35.4%		
		UAE (2)				50.40%		
						SD 35.9%		
Lohle (30)	2006	UAE					47%	
							SD 34%	
Siskin (72)	2006	UAE		27.4% (n 68)	33.2% (n 66)			
Scheurig (27)	2006	UAE			26.65% (5 months)		36.07% (14 months)	
					CI 20.25-33.81%		CI 23.34-55.02	
Volkers (32)	2006	UAE	20.9% (6 weeks)		30.90%		44.30%	48.20%
			CI 7-34.9		CI 17.3-44.5%		CI 32.5-56.2	CI 39.2-57.1
Jain (73)	2007	UAE		33%			48.90%	
				R 4.2-57.9 %			R 18.4-75.9%	
Chrisman (74)	2007	UAE				39.30%		
Toor (19)	2008	UAE (1)		34.9% (3.9 months)				
				SD 17.9%				
		UAE (2)		28.30%				
				SD 21.1%				
Firouznia (77)	2008	UAE					40%	
							SD 29.9%	
Hirst (78)	2008	UAE			42.60%			
					41.20%			
Lohle (79)	2008	UAE		31%	40%	44%		
Hald (31)	2009	UAE			51.30%			
					SD 15.4%			
Pisco (80)	2009	UAE			33.70%			
Smeets (83)	2010	UAE		42%				
Bilhim (20)	2011	UAE (1)			39%			
		UAE (2)			44.80%			
Tomislav (85)	2011	UAE		38%	57%		61%	
Kisilevsky (86)	2011	UAE		36.30%				

				SD 13.8%				
Horhoianu (88)	2012	UAE	25%					
Song (22)	2013	UAE (1)		44.90%				
		UAE (2)		42.80%				
Choi (91)	2013	UAE (1)		40.7% SD 17.6%				
		UAE (2)		36.3% SD 20.3%				
Das (90)	2013	UAE			32%			
Laios (92)	2014	UAE		42.70%			61%	
Ikink (23)	2014	UAE		35.30%				
				IQR 25-47.1%				
Dueholm (33)	2014	UAE			36.90%			
					SD 20.3%			
McLucas (94)	2015	UAE			77.30%			
					SD 14.25%			
Kim (102)	2011	MRgFUS			10.50%		14.50%	22%
Ikink (23)	2014	MRgFUS		16.30%				
				IQR 4.2-25.3%				

Table S4. Summary of relationship between percentage NPV, fibroid intensity on T2 weighted MRI and percentage fibroid volume reduction.

Author	Year	Intensity	NPV %	Fibroid volume reduction		
				3 - 6m	9 - 12m	24 - 36m
Jain (73)	2007	All fibroids		58.6%	75%	
		Hyperintense		68.1%		
		Hypointense		55.7%		
Lenard (98)	2008	Overall	16.3	13%	9.30%	
		Hyperintense	13.6	10%	0%	
		Hypointense	19.9	16%	17.20%	
Funaki (26)	2009	Hyperintense	36.2	9.10%		
		Isointense	54.0	36.5% *		39.5% *
		Hypointense	54.7			
Hindley (96)	2004		25.0	14%		
Rabinovici (97)	2007		31.0	15.0%		
Morita (99)	2008		60.0	33%		
LeBlang (101)	2010		55.0	31%		
Desai (104)	2012		88.0	30%		
Dobrotwir (103)	2012		67.0	29.0%	38%	
Ikink (23)	2014		38.0	17.2%		
Himabindu (107)	2014		70.0	40%		
Leung (105)	2014		20.0	17%		
Han (106)	2014		54.0	42%		
Thiburce (109)	2015		27.0	27%		
Tung (108)	2016		52.7	32%		

* results of isointense and hypointense fibroids reported together.

Abbreviations

SD - standard deviation

IQR - interquartile range

R - range

CI - confidence interval

MAF - mean volume of all treated fibroids

N - number of patients

Ut Vol - uterine volume pre-treatment, expressed as mls or cm³

Fib Vol - fibroid volume pre-treatment, expressed as mls or cm³

TV - transvaginal

M - mean

M - months